Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness

Clinical and Experimental Immunology

Volumn 134, Issue 1, 2003, Pages 98-106

  Hardy, Gareth A D ^a   Imami, N ^a   Sullivan, A K ^a   Pires, A ^a   Burton, C T ^a   Nelson, M R ^a   Gazzard, B G ^a   Gotch, F M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Highly active antiretroviral therapy (HAART); Interleukin 2; Interleukin 4; Lymphocyte proliferation; T cell anergy

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; INTERLEUKIN 4;

ARTICLE; CANDIDA; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLONAL ANERGY; CYTOKINE PRODUCTION; DRUG EFFECT; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CLONAL ANERGY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; INTERLEUKIN-4; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 0141650594     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02256.x     Document Type: Article

References (39)

1. Ballett JJ, Couderc L-J, Rabian-Herzog C et al. Impaired T lymphocyte dependent immune responses to microbial antigens in patients with HIV-1 associated persistent generalised lymphadenopathy. AIDS 1988; 2:291-7.
2. + lymphocytes in vivo. J Immunol 1987; 138:3725-30.
3. + T cell responses associated with control of viraemia. Science 1997; 278:1447-50.
4. + memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T cell functional defects observed in infected individuals. Proc Natl Acad Sci 1990; 87:6058-62.
5. +T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:483-4.
6. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specifcity equates with progression to disease. J Infect Dis 2000; 182:792-8.
7. Meyaard L, Schuitemaker H, Miedema F. T cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today 1993; 14:161-4.
8. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-57.
9. Romagnami S. The Th1/Th2 paradigm. Immunol Today 1997; 18:263-6.
10. + cytotoxic T cell responses during chronic viral infections. J Virol 1994; 68:8056-63.
11. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T cell immunity to influenza. N Engl J Med 1983; 309:13.
12. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long term asymptomatics. J Exp Med 1995; 8:903-7.
13. Rowland Jones SL, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64.
14. + nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995; 11:1167-73.
15. + T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol 1996; 70:4941-7.
16. O'Connor D, Friedrich T, Hughes A, Allen TM, Watkins D. Understanding cytotoxic T lymphocyte escape during simian immunodeficiency virus infection. Immunol Rev 2001; 183:115-26.
17. O'Connor DH, Allen TM, Vogel TU et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-9.
18. Clerici M, Shearer GM. A Th1 to Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107-10.
19. Champagne P, Ogg GS, King AS et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410:106-11.
20. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type-1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different disease stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177:249.
21. Gotch F, Hardy G, Imami N. Therapeutic vaccines in HIV-1 infection. Immunol Rev 1999; 170:173-82.
22. Rosenberg ES, Walker BD. HIV type-1 specific helper-T cells: a critical host defence. AIDS Res Hum Ret 1998; 14:S143-7.
23. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV infection without immunological progression. AIDS 1994; 8:1123-8.
24. Easterbrook PJ, Schrager LK. Long-term non progression in HIV infection. Methodological issues and scientific priorities. Workshop summary. AIDS Res Hum Ret 1998; 14:1211-28.
25. Perelson AS, Essunger P, Cao Y et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
26. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
27. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of HIV infected subjects treated with an HIV-specific protease inhibitor, Ritonavir. J Infect Dis 1996; 9:321-9.
28. Pakker NG, Notermans DW, de Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV infection: a composite of redistribution and proliferation. Nature Med 1998; 4:208-14.
29. Li TS, Tubiana R, Katlama C et al. Long lasting recovery in CD4 cell function and viral load reduction after highly active antiretroviral therapy in advance HIV-1 disease. Lancet 1998; 351:1682-6.
30. Pontesilli O, Kerhof-Garde S, Notermans DW et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180:76-86.
31. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
32. Imami N, Hardy GAD, Nelson MR. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active antiretroviral therapy. Clin Exp Immunol 1999; 118:78-86.
33. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76:9011-23.
34. + T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:533-40.
35. Imami N, Antonopoulos C, Hardy GAD, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: Impact of highly active antiretroviral therapy. AIDS Res Hum Ret 1999; 15:1499-508.
36. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of T cell clonal anergy by IL-2 stimulation. Int Immunol 1992; 4:661-71.
37. Marrack P, Mitchell T, Bender J, Hildeman D, Kedi R, Teague K, Kappler J. T cell survival. Immunol Rev 1998; 165:279-85.
38. Akbar AN, Borthwick N, Salmon M et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med 1993; 178:427-38.
39. + T cells undergoing apoptosis: a mechanism for T cell clearance during resolution of viral infections. J Exp Med 1994; 180:1943-7.